Napoltec Life Sciences

Napoltec Life Sciences is a private China-based drug delivery biotechnology joint venture formed by AccurEdit Therapeutics and N1 Life in 2022. The company focuses on developing next-generation therapeutic drug delivery systems intended to accelerate clinical translation of drug and gene therapy candidates. Its platform is described as using biodegradable polymers and organ-specific targeting approaches, with a particular emphasis on non-liver delivery and improved tissue penetration, bioavailability, release control, and safety. Napoltec appears to function primarily as a platform and translational delivery company rather than a clinical-stage single-asset developer. Publicly available information on a named proprietary pipeline remains limited.